Drugs / QPX7831
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04578873 | Apr 2021 → Aug 2022 | bacterial infectious disease | Qpex Biopharma, Inc. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | QPX7831 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04578873 ↗ |
| Action | Inhibit | “a beta-lactamase inhibitor” NCT04578873 ↗ |
| Route | Oral | “when administered orally” NCT04578873 ↗ |